European Journal of Heart Failure最新文献

{"title":"Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS‐MI)","authors":"Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, Bethany Stanley, Katriona J.M. Brooksbank, Ross T. Campbell, Richard Good, Pardeep S. Jhund, Peter Kellman, Ninian N. Lang, M. Mitchell Lindsay, Kenneth Mangion, Roy S. Gardner, Patrick B. Mark, Barbara Meyer, Joanne O'Donnell, Vanessa Orchard, Aadil Shaukat, Stuart Watkins, Alex McConnachie, John J.V. McMurray, Paul Welsh, Naveed Sattar, Colin Berry, Kieran F. Docherty","doi":"10.1002/ejhf.3560","DOIUrl":"https://doi.org/10.1002/ejhf.3560","url":null,"abstract":"AimsPatients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are considered to be at risk of progressive adverse cardiac remodelling which can lead to the development of heart failure and death. The early addition of a sodium–glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients.Methods and resultsWe performed a randomized, double‐blind, placebo‐controlled, multicentre trial using cardiovascular magnetic resonance imaging (MRI), in patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF &lt;45% by MRI. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome was the change in left ventricular end‐systolic volume indexed to body surface area (LVESVI) from baseline to 24 weeks. Secondary outcomes included measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and high‐sensitivity troponin I (hs‐TnI) and N‐terminal prohormone of B‐type natriuretic peptide (NT‐proBNP) concentrations. From October 2022 to January 2024, 105 eligible patients were randomized. The mean age was 63 ± 11 years and 90 (87%) were male. The mean LVEF was 34.8 ± 6.0%. In the placebo group, LVESVI decreased by 7.8 ± 16.3 ml/m<jats:sup>2</jats:sup>, left ventricular end‐diastolic volume index (LVEDVI) did not change (−0.3 ± 18.7 ml/m<jats:sup>2</jats:sup>) and LVEF increased by 8.5 ± 7.4% at 24 weeks from baseline. Empagliflozin did not affect the change in LVESVI from baseline to 24 weeks (between‐group difference = 0.3 ml/m<jats:sup>2</jats:sup>, 95% confidence interval −5.2 to 5.8; <jats:italic>p</jats:italic> = 0.92). Compared with placebo, empagliflozin also had no effect on LVEDVI, LVEF, left atrial volume index, left ventricular mass index, NT‐proBNP, or hs‐TnI, but did increase haematocrit and reduced uric acid and weight.ConclusionsIn patients with left ventricular systolic dysfunction after an acute MI receiving contemporary standard of care, treatment with empagliflozin had no effect on cardiac volumes or LVEF compared with placebo. Progressive adverse cardiac remodelling did not occur in the majority of patients.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"75 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailoring medical therapy for heart failure with preserved ejection fraction","authors":"Riccardo M. Inciardi, Mauro Riccardi, Gianluigi Savarese, Marco Metra, Muthiah Vaduganathan, Scott D. Solomon","doi":"10.1002/ejhf.3558","DOIUrl":"https://doi.org/10.1002/ejhf.3558","url":null,"abstract":"<h2> Introduction</h2>\u0000<p>Heart failure with preserved ejection fraction (HFpEF) accounts for half of the hospitalization for heart failure (HF) worldwide, and the prevalence is expected to increase along with population aging and increasing burden of cardio-kidney-metabolic disorders.<span>¹</span> Treatment options for chronic HFpEF have expanded in recent years.<span>²</span> Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are now guideline-recommended as a first-line treatment in patients with mildly reduced and preserved ejection fraction. In a meta-analysis of the EMPEROR-Preserved and DELIVER trials, SGLT2i reduced cardiovascular (CV) death or first hospitalization for HF by 20% with consistent reductions in both components (12% risk reduction in CV death and 26% risk reduction in first hospitalization for HF), among HF patients with left ventricular ejection fraction (LVEF) &gt;40%.<span>³</span> In the PARAGON-HF trial, treatment with sacubitril/valsartan led to a marginal reduction of total hospitalizations for HF and CV death compared to valsartan in patients with HF and LVEF ≥45%, with a more pronounced benefit observed in those with an LVEF below normal.<span>⁴</span> Based on the results of this trial, sacubitril/valsartan received indications for use in patients with HF with mildly reduced ejection fraction (HFmrEF) and selected patients with HFpEF with an LVEF below normal in the United States. Lastly, in the FINEARTS-HF trial, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone showed a 16% relative risk reduction of worsening HF events and death from CV causes compared to placebo among patients with HF and LVEF ≥40%.<span>⁵</span></p>\u0000<p>These advances in HFpEF pharmacotherapy, along with the substantial residual risk of this population, highlight the need for an accelerated optimization of foundational medical therapy.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"46 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries – A Global Congestive Heart Failure (G-CHF) study","authors":"Darryl P. Leong, Philip G. Joseph, Hisham Dokainish, Stefan Störk, John V.V. McMurray, Lisa M. Mielniczuk, Sanjib Kumar Sharma, Andrés Orlandini, Kamilu M. Karaye, Antoni Bayes-Genis, Tara McCready, Alex Grinvalds, Kumar Balasubramanian, Kelley R. Branch, Kristian Kragholm, Salim Yusuf","doi":"10.1002/ejhf.3550","DOIUrl":"https://doi.org/10.1002/ejhf.3550","url":null,"abstract":"The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure (HF) from countries of different income levels.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"51 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)","authors":"Adriaan A. Voors, Marco Metra, Douwe Postmus, Barry H. Greenberg, Gadi Cotter, Beth A. Davison, Iris E. Beldhuis, G. Michael Felker, Gerasimos Filippatos, Peter S. Pang, Piotr Ponikowski, Claudio Gimpelewicz, John R. Teerlink","doi":"10.1002/ejhf.3551","DOIUrl":"https://doi.org/10.1002/ejhf.3551","url":null,"abstract":"Serelaxin is recombinant human relaxin-2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy. In the RELAX-AHF trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage. In RELAX-AHF-2, organ damage-related biomarkers were assessed in a biomarker substudy.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"7 20 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142810070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of acute decompensated valvular heart disease","authors":"Enzo Lüsebrink, Hugo Lanz, Antonia Kellnar, Nicole Karam, Samir Kapadia, Raj Makkar, William T. Abraham, Azeem Latib, Martin Leon, Anna Sannino, Mony Shuvy, Mayra Guerrero, Neil Fam, Javed Butler, Marianna Adamo, Volker Rudolph, Gilbert H.L. Tang, Thomas J. Stocker, Karl-Philipp Rommel, Philipp Lurz, Holger Thiele, Steffen Massberg, Fabien Praz, Bernard Prendergast, Jörg Hausleiter","doi":"10.1002/ejhf.3549","DOIUrl":"https://doi.org/10.1002/ejhf.3549","url":null,"abstract":"Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock. Current evidence remains scarce and recommendations regarding the management of acute heart failure caused by VHD are lacking in most recent international guidelines. Herein, we review the management of acute heart failure caused by VHD with a focus on transcatheter therapies and describe currently available evidence based on a systematic literature search on the following valve pathologies: (i) aortic stenosis, (ii) aortic regurgitation, (iii) mitral regurgitation, and (iv) mitral stenosis. Articles reporting outcomes following urgent or emergent valve intervention in the setting of cardiogenic shock or acute heart failure were considered. After screening a total of 2234 articles, 76 published between 1994 and 2023 were included in subsequent analysis. Based on available evidence, proposed treatment algorithms to guide optimal management of acute heart failure caused by VHD were created. As the number of patients presenting with acute heart failure caused by VHD continues to rise and outcomes following transcatheter valve interventions continue to improve, it is inevitable that minimally invasive options will play an increasingly important role in the acute setting, especially given these patients are at an increased operative risk. This review aims to present an organized approach to the complex management and interventional treatment of patients with acute heart failure caused by VHD.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"1 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142810072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailored therapies for patients affected by systemic sclerosis with primary heart involvement: The role of rituximab","authors":"Daniela Tomasoni, Enrico Ammirati, Marco Metra","doi":"10.1002/ejhf.3543","DOIUrl":"https://doi.org/10.1002/ejhf.3543","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"21 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction","authors":"Luca Monzo, Emmanuel Bresso, Kenneth Dickstein, Bertram Pitt, John G.F. Cleland, Stefan D. Anker, Carolyn S.P. Lam, Mandeep R. Mehra, Dirk J. van Veldhuisen, Barry Greenberg, Faiez Zannad, Nicolas Girerd","doi":"10.1002/ejhf.3547","DOIUrl":"https://doi.org/10.1002/ejhf.3547","url":null,"abstract":"Patients experiencing ischaemic heart failure with reduced ejection fraction (HFrEF) represent a diverse group. We hypothesize that machine learning clustering can help separate distinctive patient phenotypes, paving the way for personalized management.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"19 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term rate of heart failure in patients with autoimmune disease: A nationwide cohort study","authors":"Guoli Sun, Emil L. Fosbøl, Mikkel Faurschou, Morten Schou, Christian Torp-Pedersen, Lars Køber, Jawad H. Butt","doi":"10.1002/ejhf.3541","DOIUrl":"https://doi.org/10.1002/ejhf.3541","url":null,"abstract":"Although certain autoimmune diseases (AIDs) have been associated with an increased rate of heart failure (HF), data on the long-term rate of HF across the spectrum of AIDs are lacking. We investigated the long-term rate of HF in individuals with a history of 28 different AIDs.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"38 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endomyocardial biopsy in the diagnosis of cardiac sarcoidosis","authors":"Henriikka Mälkönen, Jukka Lehtonen, Pauli Pöyhönen, Valtteri Uusitalo, Mikko I. Mäyränpää, Markku Kupari","doi":"10.1002/ejhf.3545","DOIUrl":"https://doi.org/10.1002/ejhf.3545","url":null,"abstract":"AimsWe set out to assess the utility of endomyocardial biopsy (EMB) in cardiac sarcoidosis (CS). Historically, EMB sensitivity in CS is only ≤25%, but comprehensive analyses of its current diagnostic performance are not available.Methods and resultsThe data of 260 consecutive patients with <jats:styled-content style=\"fixed-case\">CS</jats:styled-content> (mean age 49 years, 60% female) meeting the Heart Rhythm Society diagnostic criteria were analysed retrospectively. Overall, 216 patients (83%) had undergone <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content>, 47 with repeat procedures. <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> overall sensitivity was 38%, rising to 49% after repeat biopsies. On logistic regression analysis, positive <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> was predicted independently by presentation with ventricular tachyarrhythmia with an odds ratio (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content>) of 3.8 (95% confidence interval [CI] 1.2–12.0, <jats:italic>p</jats:italic> = 0.021), left ventricular ejection fraction ≤45% (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content> 3.7, 95% CI 1.5–9.1, <jats:italic>p</jats:italic> = 0.004), elevation of cardiac troponins (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content> 2.7, 95% CI 1.1–6.4, <jats:italic>p</jats:italic> = 0.024), and presence of late gadolinium enhancement in left ventricular mid‐apical septal segments on magnetic resonance imaging (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content> 4.1, 95% CI 1.2–13.8, <jats:italic>p</jats:italic> = 0.024). <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> sensitivity, counting in repeats, was 16% in patients (<jats:italic>n</jats:italic> = 37) without any independent predictor versus 38%, 60%, 79%, and 88% in those with 1 (<jats:italic>n</jats:italic> = 76), 2 (<jats:italic>n</jats:italic> = 62), 3 (<jats:italic>n</jats:italic> = 33), and 4/4 (<jats:italic>n</jats:italic> = 8) predictors, respectively. The rate of serious complications was 0.7% without mortality or permanent harm. Positive <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> was not an independent predictor of prognosis.ConclusionThe sensitivity of <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> in <jats:styled-content style=\"fixed-case\">CS</jats:styled-content> depends on the extent, activity, and location of myocardial involvement, being the higher the more severe <jats:styled-content style=\"fixed-case\">CS</jats:styled-content> is. Its use should rely on weighing the pre‐test likelihood and individual value of positive biopsy against the procedural risks.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy","authors":"Lawrence Zeldin, Joanna B.S. Eichler, Sergio L. Teruya, Ariel Y. Weinsaft, Alfonsina Mirabal, Margaret O. Cuomo, Kimberly Mateo, Stephen Helmke, Mathew S. Maurer","doi":"10.1002/ejhf.3540","DOIUrl":"https://doi.org/10.1002/ejhf.3540","url":null,"abstract":"Transthyretin cardiomyopathy (ATTR-CM) is characterized by episodes of worsening heart failure (WHF) which can include heart failure (HF) hospitalizations or urgent unplanned visits for administration of intravenous diuretics. WHF characterized by outpatient intensification of oral loop diuretics is common yet its prognostic implications for ATTR-CM patients relative to other WHF events remains unclear. We assessed how WHF characterized by outpatient diuretic intensification (ODI) relates to mortality in this population.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"79 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}